Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252674 | 0.86 | NLRP3 (0.76) | NLRP3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL24294950 | 0.85 | NLRP3 (0.74) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL593363 | 0.85 | NLRP3 (0.74) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL8233038 | 0.85 | NLRP3 (0.74) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL13299519 | 0.84 | NLRP3 (0.72) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL13299534 | 0.84 | NLRP3 (0.72) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL5009162 | 0.83 | KDM4E (0.77) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL11766544 | 0.81 | NLRP3 (0.68) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| Hydrochloric Acid SCHEMBL11373081 | 0.81 | NLRP3 (0.68) | NLRP3KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL13816155 | 0.81 | NLRP3 (0.68) | NLRP3KDM4EALDH1A1HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | KULKARNI ASHISH (US) | 2026-04-02 | — | — | US | claimed |
| US-20250375534-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | BioNTech SE (DE) | 2025-12-11 | — | — | US | claimed |
| EP-4518845-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | BioNTech SE (DE) | 2025-03-12 | — | — | EP | claimed |
| CN-119562807-A | Complexes for delivery of nucleic acids | 生物技术公司 | 2025-03-04 | — | — | CN | claimed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | claimed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | claimed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| WO-2023232747-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | BioNTech SE (DE) | 2023-12-07 | — | — | WO | claimed |
| US-20230295588-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE BASED ON HOST-MYCOBIOTA INTERACTIONS | CORNELL UNIVERSITY (US) | 2023-09-21 | — | — | US | claimed |
| CN-116392595-A | Application of scorch signal path inhibitor in preparation of orthodontic tooth root absorption medicine | 四川大学 | 2023-07-07 | — | — | CN | claimed |
| US-20230146308-A1 | METHOD FOR THE TREATMENT NLRP3-ASSOCIATED DISEASES | SOFTHALE NV (BE) | 2023-05-11 | — | — | US | claimed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | claimed |
| EP-4121032-A1 | METHOD FOR THE TREATMENT NLRP3-ASSOCIATED DISEASES | Softhale NV (BE) | 2023-01-25 | — | — | EP | claimed |
| CN-115297855-A | Methods of treating NLRP 3-associated diseases | 索芙特海尔公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2021185912-A1 | METHOD FOR THE TREATMENT NLRP3-ASSOCIATED DISEASES | SOFTHALE NV (BE) | 2021-09-23 | — | — | WO | claimed |
| US-12624010-B2 | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway | AC IMMUNE SA (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | KULKARNI ASHISH (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2010056669-A1 | PHOSPHORESCENT EMITTERS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20080292904-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS | SONY CORPORATION (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080292904-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS | SONY CORPORATION (JP) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624010-B2 | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway | NOD1, NLRP3, NLRP1 | NLRP3 2/4885KDM4E 4615/4885ALDH1A1 843/4885 |
| US-20250375534-A1 | COMPLEXES FOR DELIVERY OF NUCLEIC ACIDS | TLR3, TLR9, SARNP | NLRP3 1805/4885KDM4E 4444/4885ALDH1A1 4446/4885 |
| US-20260091162-A1 | SPRAYABLE POLYMERIC SCAFFOLD LOADED WITH INFLAMMASOME-INHIBITING LIPID NANORODS FOR ANTI-INFLAMMATION THERAPY | NLRP3, NLRP1, IL1B | NLRP3 1/4885KDM4E 2645/4885ALDH1A1 1965/4885 |
| US-20230146308-A1 | METHOD FOR THE TREATMENT NLRP3-ASSOCIATED DISEASES | NLRP3, NLRP1, NOD1 | NLRP3 1/4885KDM4E 4228/4885ALDH1A1 3279/4885 |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | NLRP3 2321/4885KDM4E 3229/4885ALDH1A1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.